Skip to main content
TipRanks
Go Ultimate75% OFF

Solvonis Therapeutics (J4I) AI Stock Analysis

0 Followers
DE:J4I

Solvonis Therapeutics

(Frankfurt:J4I)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low LeverageMinimal debt lowers the company’s fixed financial burden and reduces exposure to refinancing or interest-payment pressure. This gives Solvonis greater flexibility to preserve resources, pursue development priorities, or absorb operating volatility while it works toward a sustainable business model.
Negative Factors
Persistent LossesRecurring operating and net losses show that Solvonis has not yet demonstrated a profitable operating model. Continued losses can consume the company’s financial resources, weaken equity over time, and limit its ability to fund development or expansion without additional capital.

Solvonis Therapeutics (J4I) vs. iShares MSCI Germany ETF (EWG)

Not enough price history over this period.

Market Cap
EUR 6.13M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.1
Beta (1Y)
-2.13
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
6
Sector
Industrials
Sector Strength
63
Industry
Biotechnology

Solvonis Therapeutics Business Overview & Revenue Model

Company Description

Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatr...

Solvonis Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

DE:J4I against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:IMIGB:IMI70OutperformGBP 6.76B21.2832.41%1.21%7.67%45.97%
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
GB:AVGGB:AVG62NeutralGBP 280.68M38.385.57%0.67%4.43%2.67%
GB:SMINGB:SMIN61NeutralGBP 7.31B4.2892.97%1.80%-33.55%4.29%
GB:MGAMGB:MGAM58NeutralGBP 743.56M40.395.79%4.54%-5.58%-32.73%
GB:MPACGB:MPAC45NeutralGBP 103.00M-13.88-10.45%―9.04%40.78%

* Industrials Sector Average

Performance Comparison

-40%-20%0%20%40%GB:AVGGB:IMIGB:MPACGB:MGAMGB:SMINDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:J4I and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:J4ISolvonis Therapeutics plc―――
GB:AVGAvingtrans plc760.00253.6250.08%
GB:IMIIMI plc2916.00512.7621.34%
GB:MPACMpac Group PLC342.50-7.50-2.14%
GB:MGAMMorgan Advanced Materials269.0083.1644.75%
GB:SMINSmiths Group plc2692.00273.6411.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.